Celgene (CELG), Acceleron (XLRN) Report Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III BELIEVE Study in Adults with Transfusion-Dependent Beta-Thalassemia
Tweet Send to a Friend
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
